Eileen A. Kamerick
Eileen A. Kamerick's purchase track record
Eileen A. Kamerick has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/20/2022 | SCD | $20K | +2.1% | +10.0% | +14.8% |
| 12/20/2022 | IGI | $20K | +3.7% | +1.9% | +14.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Copart extends tender offer to acquire ACV Auctions. Copart has announced an extension of its tender offer to acquire ACV Auctions. This development highlights ongoing interest in the company, with some analysts suggesting that current market conditions may be masking long-term growth potential. The stock is currently trading near its 52-week high, reflecting the attention surrounding the acquisition proposal.
Transaction History
| ASB | ▲ Buy | Grant | 345 | $10K | 9/15/2026 | View on chart |
| ASB | ▲ Buy | Grant | 36 | $1K | 9/15/2026 | View on chart |
| ASB | ▲ Buy | Grant | 355 | $10K | 6/15/2026 | View on chart |
| ASB | ▲ Buy | Grant | 38 | $1K | 6/15/2026 | View on chart |
| ACVA | ▲ Buy | Grant | 27,500 | $0 | 5/27/2026 | View on chart |
| ASB | ▲ Buy | Grant | 44 | $1K | 3/16/2026 | View on chart |
| ASB | ▲ Buy | Grant | 417 | $10K | 3/16/2026 | View on chart |
| ASB | ▼ Sell | Open Market | 6,600 | $185K | 2/19/2026 | View on chart |
| ASB | ▲ Buy | Grant | 4,585 | $125K | 2/1/2026 | View on chart |
| ASB | ▲ Buy | Grant | 45 | $1K | 12/15/2025 | View on chart |
| ASB | ▲ Buy | Grant | 377 | $10K | 12/15/2025 | View on chart |
| ASB | ▲ Buy | Grant | 45 | $1K | 9/15/2025 | View on chart |
| ASB | ▲ Buy | Grant | 372 | $10K | 9/15/2025 | View on chart |
| ASB | ▲ Buy | Grant | 50 | $1K | 6/16/2025 | View on chart |
| ASB | ▲ Buy | Grant | 417 | $10K | 6/16/2025 | View on chart |
| ACVA | ▼ Sell | Open Market | 9,239 | $154K | 6/10/2025 | View on chart |
| ACVA | ▲ Buy | Grant | 9,868 | $0 | 5/28/2025 | View on chart |
| ASB | ▲ Buy | Grant | 51 | $1K | 3/17/2025 | View on chart |
| ASB | ▲ Buy | Grant | 427 | $9K | 3/17/2025 | View on chart |
| ASB | ▼ Sell | Open Market | 7,000 | $173K | 3/3/2025 | View on chart |
| ASB | ▲ Buy | Grant | 4,972 | $125K | 2/1/2025 | View on chart |
| ASB | ▲ Buy | Grant | 55 | $1K | 12/16/2024 | View on chart |
| ASB | ▲ Buy | Grant | 366 | $9K | 12/16/2024 | View on chart |
| ASB | ▲ Buy | Grant | 63 | $1K | 9/16/2024 | View on chart |
| ASB | ▲ Buy | Grant | 416 | $9K | 9/16/2024 | View on chart |
| ACVA | ▲ Buy | Option Exercise | 25,000 | — | 9/4/2024 | View on chart |
| ACVA | ▼ Sell | Open Market | 25,000 | $446K | 9/4/2024 | View on chart |
| ASB | ▼ Sell | Gift | 500 | — | 7/23/2024 | View on chart |
| ASB | ▲ Buy | Grant | 65 | $1K | 6/17/2024 | View on chart |
| ASB | ▲ Buy | Grant | 436 | $9K | 6/17/2024 | View on chart |
| ACVA | ▲ Buy | Grant | 9,239 | $0 | 5/29/2024 | View on chart |
| ASB | ▲ Buy | Grant | 65 | $1K | 3/15/2024 | View on chart |
| ASB | ▲ Buy | Grant | 431 | $9K | 3/15/2024 | View on chart |
| ACVA | ▲ Buy | Option Exercise | 12,498 | — | 3/14/2024 | View on chart |
| ACVA | ▼ Sell | Open Market | 12,498 | $217K | 3/14/2024 | View on chart |
| ASB | ▼ Sell | Open Market | 100 | $2K | 3/5/2024 | View on chart |
| ASB | ▼ Sell | Open Market | 4,900 | $103K | 3/5/2024 | View on chart |
| ASB | ▲ Buy | Grant | 5,998 | $125K | 2/1/2024 | View on chart |
| ASB | ▲ Buy | Grant | 59 | $1K | 12/15/2023 | View on chart |
| ASB | ▲ Buy | Grant | 407 | $9K | 12/15/2023 | View on chart |
| ASB | ▼ Sell | Gift | 1,500 | — | 12/7/2023 | View on chart |
| ASB | ▲ Buy | Grant | 66 | $1K | 9/15/2023 | View on chart |
| ASB | ▲ Buy | Grant | 462 | $8K | 9/15/2023 | View on chart |
| ASB | ▲ Buy | Grant | 67 | $1K | 6/15/2023 | View on chart |
| ASB | ▲ Buy | Grant | 534 | $9K | 6/15/2023 | View on chart |
| ACVA | ▲ Buy | Option Exercise | 25,000 | — | 5/25/2023 | View on chart |
| ACVA | ▼ Sell | Open Market | 25,000 | $430K | 5/25/2023 | View on chart |
| ASB | ▲ Buy | Grant | 414 | $8K | 3/15/2023 | View on chart |
| ASB | ▲ Buy | Grant | 60 | $1K | 3/15/2023 | View on chart |
| ASB | ▼ Sell | Open Market | 5,000 | $120K | 2/8/2023 | View on chart |
| ASB | ▲ Buy | Grant | 5,499 | $125K | 2/1/2023 | View on chart |
| IGI | ▲ Buy | Open Market | 1,210 | $20K | 12/20/2022 | View on chart |
| SCD | ▲ Buy | Open Market | 1,670 | $20K | 12/20/2022 | View on chart |
| ASB | ▲ Buy | Grant | 355 | $8K | 12/15/2022 | View on chart |
| ASB | ▲ Buy | Grant | 47 | $1K | 12/15/2022 | View on chart |
| ASB | ▼ Sell | Gift | 1,000 | — | 11/30/2022 | View on chart |
| ASB | ▲ Buy | Grant | 47 | $993 | 9/15/2022 | View on chart |
| ASB | ▲ Buy | Grant | 352 | $7K | 9/15/2022 | View on chart |
| ASB | ▼ Sell | Open Market | 4,000 | $81K | 9/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Barclays Raises ASB Price Target to $35, Maintains Overweight
Barclays has raised its price target for Associated Banc-Corp to $35 while maintaining an Overweight rating. This move aligns with the broader analyst consensus, where the average target is $34.20. The stock is currently trading near its 52-week high, reflecting recent strength compared to some finance peers. Investors are also awaiting the company's third-quarter earnings report scheduled for late October.
Barclays Raises ASB Price Target to $35, Maintains Overweight. Barclays has raised its price target for Associated Banc-Corp to $35 while maintaining an Overweight rating. This move aligns with the broader analyst consensus, where the average target is $34.20. The stock is currently trading near its 52-week high, reflecting recent strength compared to some finance peers. Investors are also awaiting the company's third-quarter earnings report scheduled for late October.